Zogenix Completes Enrollment of Phase 3 Trial

Pharmaceutical Investing

Zogenix announced the last patient entered the randomized treatment period for the company’s Phase 3 clinical trial of ZX008 as an adjunctive treatment for seizures caused by Dravet syndrome.

Zogenix (NASDAQ:ZGNX) announced the last patient entered the randomized treatment period for the company’s Phase 3 clinical trial of ZX008 as an adjunctive treatment for seizures caused by Dravet syndrome.
As quoted in the press release:

“The completion of patient randomization in Study 1 is an important milestone for our ZX008 Phase 3 development program in Dravet syndrome,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “We look forward to the availability of top-line data from this study, which we expect in the third quarter of this year.  We are grateful for the participation of the patients, their families and the investigators involved in our ongoing clinical program.”
Study 1 is a three-arm, fixed-dose, placebo-controlled trial with 40 subjects per treatment group being conducted in the U.S., Canada, Europe, and Australia.  Randomized subjects are titrated to their target dose (0.2 or 0.8 mg/kg/day ZX008, maximum of 30 mg/day, or placebo) over two weeks and then held at that fixed dose for 12 weeks of maintenance treatment. Subjects who complete Study 1 are eligible to enter a long-term, open-label extension study.
In addition to Study 1, Zogenix is conducting a second double-blind, randomized, two-arm pivotal Phase 3 trial, Study 1504, in which all patients will be taking stiripentol, valproate and clobazam as part of their baseline standard care.  In February 2017, the Company announced the initiation of the safety and efficacy portion of Study 1504, which compares a single dose of ZX008 versus placebo across the titration and 12-week maintenance periods.  Study 1504 will enroll 40 subjects per treatment group.

Click here to read the full press release.

The Conversation (0)
×